Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-20-012905
Filing Date
2020-11-05
Accepted
2020-11-05 16:40:23
Documents
70
Period of Report
2020-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q ymab-20200930x10q.htm   iXBRL 10-Q 1949419
2 EX-10.8 ymab-20200930xex10d8.htm EX-10.8 95706
3 EX-10.9 ymab-20200930xex10d9.htm EX-10.9 93363
4 EX-31.1 ymab-20200930xex31d1.htm EX-31.1 15729
5 EX-31.2 ymab-20200930xex31d2.htm EX-31.2 15638
6 EX-32.1 ymab-20200930xex32d1.htm EX-32.1 7794
7 EX-32.2 ymab-20200930xex32d2.htm EX-32.2 7751
  Complete submission text file 0001558370-20-012905.txt   7010172

Data Files

Seq Description Document Type Size
8 EX-101.SCH ymab-20200930.xsd EX-101.SCH 46706
9 EX-101.CAL ymab-20200930_cal.xml EX-101.CAL 36145
10 EX-101.DEF ymab-20200930_def.xml EX-101.DEF 174186
11 EX-101.LAB ymab-20200930_lab.xml EX-101.LAB 419944
12 EX-101.PRE ymab-20200930_pre.xml EX-101.PRE 342376
13 EXTRACTED XBRL INSTANCE DOCUMENT ymab-20200930x10q_htm.xml XML 1040998
Mailing Address 750 THIRD AVENUE 9TH FLOOR NEW YORK NY 10017
Business Address 750 THIRD AVENUE 9TH FLOOR NEW YORK NY 10017 212-847-9841
Y-mAbs Therapeutics, Inc. (Filer) CIK: 0001722964 (see all company filings)

EIN.: 474619612 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38650 | Film No.: 201291142
SIC: 2834 Pharmaceutical Preparations